Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
  • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
  • C07K16/065—Purification, fragmentation
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/531—Production of immunochemical test materials
  • G01N33/532—Production of labelled immunochemicals

Definitions

• the present invention relates to an immunoreactive compound and a pharmaceutical preparation comprising the same.
• Such an immunoreactive compound can particularly be used in immunotherapy and in diagnosis.
• Immunotherapy is one of the promising possibilities to fight a number of diseases.
• the principle of immunotherapy itself is old. It comprises a targeting moiety which delivers an active substance to the immediate vicinity of the target.
• Ligand- receptor interactions or antibody-antigen interactions are suitable couples of targeting moiety and target, but others can of course be envisioned by the person skilled in the art.
• pretargeting strategies include, but are not limited to, prodrug activation, whereby an enzyme is coupled to a targeting moiety, which is administered before or together with a prodrug which is less toxic than its parent drug and which enzyme converts the prodrug into the parent drug at the target site.
• antibodies coupled to a label For anti-tumour therapy and tumour localization, and for cancer diagnosis generally use is made of antibodies coupled to a label.
• a label can be e.g. a toxic compound such as adriamycin, verrucarin, calicheamycin, mitomycin, ricin a, or any other suitable toxic compound, or an isotope or, as described above an enzyme.
• the antibodies generally are targeted against a particular antigen of the tumour.
• the antibodies used for this purpose in most cases are monoclonal antibodies of murine origin. Murine monoclonal antibodies are easy to obtain according to well established methods, and against virtually any antigen.
• tumour material is administered to mice these develop antibodies against almost any antigen of the tumour material, including the normal antigens of these cells. In this way it is difficult to obtain antibodies specific for tumour cells only.
• murine antibodies may be directed to epitopes that are not tumour-specific according to the human immune repertoire.
• a solution has been sought in the use of antibody fragments mainly containing the antigen binding domain of the murine antibody, which may overcome the second, but certainly not the first problem.
• Human anti-tumour antibodies can suitably be obtained according to the method described in EP 0151030.
• a problem is, however, that this method mainly yields immunoglobulins of the IgM and/or IgA type. These are in fact pentameric or dimeric, i.e. they are composed of five or two monomers interconnected via S-S bridges, whereas each of these IgM/IgA monomers is composed of two heavy and two light chains and contains two antigen binding sites. Each of these monomers roughly equals an IgG molecule in size. Hence a complete IgM molecule is about five times the size of an intact IgG molecule.
• IgM's are characterized by antigen-affinities which are at the low end of the IgG affinity range.
• the present invention is concerned with the restoration of the antigen affinity of fragments of IgM.
• the affinity of antigen binding IgM or IgA fragments can be restored by coupling them to at least one polypeptide.
• Such a polypeptide can advantageously be a human protein such as human serum albumin, or a (human) enzyme, or it can be a synthetic polypeptide with a low immunogenicity such a poly-L-glutamic acid or poly-L-lysine.
• the IgM or IgA fragment either can be an IgM or an IgA monomer, which can be obtained by reducing the S-S bonds between the monomers, or can be an antigen binding fragment obtained after enzymatic cleavage of the IgM or the IgA, e.g. by use of pepsin or papain.
• F(ab')2 Digestion with pepsin delivers an antibody fragment generally indicated as F(ab')2 which in turn is composed of two antigen bindings parts interconnected by S-S bonds. Reduction of these bonds yields two F(ab') fragments.
• Both IgM or IgA monomers and F(ab ! ) fragments ideally can be bound to the polypeptide(s) via their sulphur atom.
• binding of the IgM fragment to the polypeptide can be by any other suitable bond, as long as the antigen binding characteristics are not hampered. In this respect it is also convenient to establish a binding via glycosyl groups if present at the constant region of the IgM or IgA fragment.
• the bond between the IgM or IgA fragment and the polypeptide can either be a direct link or an indirect link via a linking group and/or a spacer.
• the bond between the IgM or IgA fragment and the polypeptide can be established by making available on both components a group suitable for linking, optionally reacting either or both linking groups with a linker and/or spacer, and thereafter reacting the components to form the desired immunoreactive compound.
• the polypeptide can be labelled with one or more therapeutically or diagnostically useful groups prior to or after the coupling to the IgM or IgA fragment.
• Suitable therapeutically useful groups are e.g. cytotoxic drugs, (optionally chelated) radioactive atoms, or enzymes for the conversion of prodrugs into active drugs.
• the polypeptide is an enzyme itself, which is able to convert a prodrug into a drug at the target site, there is an additional advantage, because the size of the immunoreactive compound plays an important role in its applicability.
• Suitable diagnostically useful groups are e.g. (optionally chelated) radioactive atoms.
• the IgM or IgA fragment advantageously is obtained from human IgM or IgA. This IgM or IgA is directed against an antigen specific for, or derived from the tumour, which may be found either in or on or outside the tumour cells.
• IgM (3-5 mg/ml) was incubated in 10 mmol/1 cysteine in PBS (6.7 mmol/1 K/Na phosphate buffer PH 6.5; 0.13 mol/1 NaCl) for 3 h at 37 °C. Buffers were saturated with nitrogen and the reaction vessel was closed gas-tight. After incubation, the reaction mixture was chromatographed on Sephadex G25, equilibrated with 1 mmol/1 cysteine in PBS. Monomers were precipitated with (NH 4 ) 2 S ⁇ 4 at 50% saturation and dissolved in a minimal volume of 1 mmol/1 cysteine in PBS PH 7.5.
• the monomer solution was applied on a Fractogel TSK HW 55 (S) column equilibrated in 1 mmol/1 cysteine in PBS PH 7.5.
• the bed volume of the column was 45 times that of the volume applied and the elution rate was 0.06 bed volume/h.
• Solid DTNB dithionitrobenzoic acid, Ellman's reagent
• HSA(-DTPA) was dissolved to a concentration of 5- 10 mg/ml in 0.1 mol/1 sodium phosphate; 0.1 mol/1 NaCl; 5 mmol/1 EDTA PH 7.5.
• DTT dithio-threitol
• Solution B Solution B
• HSA(-DTPA) was removed by (NH ) 2 S0 4 precipitation at 50% saturation. Conjugate and non- conjugated monomers were precipitated, whereas HSA(- DTPA) remains in solution.
• the precipitate was washed several times with 50 % saturated (NH ) 2 S0 4 and was dissolved in a minimal volume of 0.1 mol/1 sodium phosphate, 5 mmol/1 EDTA PH 7.5. The solution was chromatographed on Sephadex G25 equilibrated in the EDTA phosphate buffer (buffer A) (devoid of NaCl 1 ! ) .
• the protein-containing fraction was then applied on a Q-Sepharose (Fast Flow) column equilibrated in buffer A in order to separate non-conjugated monomers from the immunoconjugate by anion-exchange chromatography.
• the Q-Sepharose column was washed with buffer A until the A 8u nad returned to baseline level. Proteins retained by the column were eluted by stepwise increasing the NaCl concentration from 0 - 0.6 mol/1 NaCl.
• IgM was digested with pepsin according to the method of Putnam. Briefly, whole IgM at a concentration of 2-5 mg/ml in 0.1 mol/1 sodium acetate buffer PH 4.0 was incubated with pepsin (0.08-0.2 mg/ml) for 8 h at 4 °C. The reaction mixture was chromatographed on Fractogel H 55S equilibrated in buffer A in order to purify the F(ab') 2 fragments formed from whole, undigested IgM and low molecular weight fragments. In this way, chromatographically pure F(ab') 2 was isolated at a 40-60% yield.
• F(ab') 2 was reduced with DTT and coupled to HSA(- DTPA) in the way described for the monomers.
• Purification of F(ab ! )-HSA(-DTPA) was achieved by anion exchange chromatography on Q-sepharose and gel filtration on Fractogel as described above. The final prep was sterilised by filtration and stored at 4 °C.
• E ampl 3
• IgM Ffab o fragments IgM monomer-HSA(-DTPA) and IgM Fab'-HSAf- DTPA)-immunoconiugates.
• Immunoreactivity was determined by either an antigen binding assay or competitive EIA.
• dilution series to be tested are incubated with a given amount of peroxidase-labelled whole IgM for 3 h at ambient temperature in an microtitre plate coated with 0.1 ⁇ g/ l antigen solution. After incubation, the contents of the wells is discarded and the plates are washed three times with PBS-Tween buffer. Enzyme activity is detected with a substrate solution containing tetra ethylbenzidine as hydrogen donor. The enzyme reaction was stopped with 2 mol/1 H S0 and the absorbance was read at 450 nm.
• purified HSA(-DTPA) conjugates of monomers exhibit an immunoreactivity identical to that of whole IgM and F(ab')-HSA(-DTPA) conjugates show some immunoreactivity comparable to that of purified monomers.
• covalent attachment of a (carrier) protein e.g. through disulphide or thioether bridges, is able to restore the immunoreactivity of IgM monomers or fragments considerably, even to full extent in case of monomers.
• the reaction mixture was incubated for 16 hours at room temperature in the dark.
• the conjugate was recovered by addition of an equal volume of 100 % satured ammonium sulph.
• the precipitate was washed three times with 50 % saturated ammonium sulph, before being dissolved in an appropiate buffer.
• the enzyme was activated by SPDP us described in method A.
• the activated enzyme was chromati chargedd on a Sephadex G-25 (M) column equilibrated in 0,1 M NaAc pH 4,5; 0,1 M NaCl.
• To the enzyme containing fractions 1/20 volume of 1M DTT was added and incubation was performed for at least 30 minutes at room temperature in the dark.
• the monomerie IgM was chromatographed over Sephadex G-25 (M) into : 50 mM Tris-HCL pH 8 140 mM NaCl
• the immuno reactivity of the enzyme conjugates was determined by incubation of the conjugate with a icrotiter plate coated with crude antigen mixture of a tumour cell line expressing antigens that are recognized by Monoclonal antibodies 16.88 and 81AV78 (shown in fig. 1).
• Mab 16.88 recognices specifically a tumour-associated epitope on cytokeratins, whereas Mab 81MV78 reacts with a tumour-associated antigen at the surface of the cells.
• Myeloma is an antibody (IgM) recognizing an antigen not present in the mixture of crude antigens.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Immunology (AREA)
• Engineering & Computer Science (AREA)
• Medicinal Chemistry (AREA)
• Molecular Biology (AREA)
• General Health & Medical Sciences (AREA)
• Urology & Nephrology (AREA)
• Hematology (AREA)
• Biomedical Technology (AREA)
• Biochemistry (AREA)
• Cell Biology (AREA)
• Animal Behavior & Ethology (AREA)
• General Physics & Mathematics (AREA)
• Organic Chemistry (AREA)
• Veterinary Medicine (AREA)
• Biotechnology (AREA)
• Public Health (AREA)
• Microbiology (AREA)
• Epidemiology (AREA)
• Pharmacology & Pharmacy (AREA)
• Food Science & Technology (AREA)
• Physics & Mathematics (AREA)
• Analytical Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Pathology (AREA)
• Hospice & Palliative Care (AREA)
• Inorganic Chemistry (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Oncology (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Management, Administration, Business Operations System, And Electronic Commerce (AREA)
• Enzymes And Modification Thereof (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=8205056

Family Applications (1)

Country Status (7)

Families Citing this family (1)

Family Cites Families (11)

• 1991
  • 1991-06-28 CA CA002086531A patent/CA2086531A1/en not_active Abandoned
  • 1991-06-28 WO PCT/EP1991/001223 patent/WO1992000763A1/en not_active Application Discontinuation
  • 1991-06-28 HU HU9204170A patent/HUT63343A/hu unknown
  • 1991-06-28 EP EP91911923A patent/EP0537222A1/de not_active Withdrawn
  • 1991-06-28 KR KR1019920703408A patent/KR930701201A/ko not_active Application Discontinuation
  • 1991-06-28 JP JP91511093A patent/JPH05507924A/ja active Pending
• 1992
  • 1992-12-21 FI FI925804A patent/FI925804A0/fi unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events